Inovio started human clinical trials in the USA for developing the COVID-19 vaccine after the US FDA accepted Inovio Pharmaceuticals’ IND application for INO-4800 vaccine candidate. This is the US’s second such human trial receiving approval. The company is backed by Bill and Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI) and VGXI, Inc. This vaccine candidate will work by injecting an independent genetic structure called plasmid into a patient. This will help the patient to produce an effective antibody to fight COVID-19. Each trial participant will receive two doses of the INO-4800 vaccine four weeks apart. Safety data and immune responses can be expected by late summer. The additional preclinical trials, challenge studies will continue in parallel to this phase-1 clinical trial
COVID-19 vaccine by Inovio
